Table 1.
Patient Characteristics
| Group 1 | Group 2 | Overall | |
|---|---|---|---|
| Mitotane | Nonmitotane | ||
| (N = 6) | (N = 4) | (N = 10) | |
| Agea, mean (range), y | 55.8 (26-71) | 59 (57-61) | 57.1 (26-71) |
| Female, No. | 4 | 3 | 7 |
| Years since diagnosisa, mean (range) | 3.0 (1-4) | 7.8 (1-18) | 4.9 (1-18) |
| ENSAT stagea, No. | |||
| I | 1 | 2 | 3 |
| II | 0 | 1 | 1 |
| III | 1 | 0 | 1 |
| IV | 4 | 1 | 5 |
| Hormone production, No. | |||
| None | 4 | 3 | 7 |
| Cortisol | 1 | 1 | 2 |
| Cortisol and androgens | 1 | 0 | 1 |
| Therapy, No. | |||
| Surgery | 5 | 4 | 9 |
| Mitotane | 6 | 1b | 7 |
| Radiotherapy | 2 | 0 | 2 |
| Chemotherapy | 0 | 0 | 0 |
| Response (RECIST)a, No. | |||
| Complete response | 2 | 3 | 5 |
| Stable disease | 3 | 0 | 3 |
| Progressive disease | 1 | 1 | 2 |
Abbreviations: ENSAT, European Network for the Study of Adrenal Tumors; RECIST, Response Evaluation Criteria in Solid Tumors.
aAt time of focus group. bDiscontinued after 5 weeks because of side effects.